Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations …
With the exception of its purchase of Genentech Inc. in 2008 ... Perhaps Shire feels it can sit back and let an auction push the stock price -- still below its one-year high of 50.21 pounds -- further skywards. But its standalone defense isn't …
Biotechnology firms MedImmune and Genentech settled a lawsuit over a patented ... Fourth-quarter sales of Synagis were $480 million. Genentech's stock rose 67 cents yesterday, to $68.89, and AstraZeneca's shares rose 1 cent, to …
The Private Placement was priced after close of trading on Oslo Stock Exchange yesterday at a subscription ... LLC., …
its US partner, for $89 a share in cash to solidity its position in cancer medicines. The lawsuit contends Roche’s bid was timed to capitalize on general market turmoil and a decline in Genentech’s stock price.
Curis' revenue for Q4 FY17 mainly included royalty revenues recorded on Genentech and Roche's net sales of Erivedge ... the end of FY17 compared to $19.86 million at the end of FY16. Stock Performance Snapshot April 18, 2018 - At …
Genentech shares rose 3.7 percent to $72.48 in extended trading from their New York Stock Exchange close at $69.92.
Avastin should soon surpass $2 billion in annual sales, and that helped push Genentech stock up 30 percent in the last two weeks. The rosy financial forecast is easy to see when investors do the math: Nearly 100,000 people are …
NewLink Genetics Corp. (NASDAQ: NLNK) announced that it has entered into an exclusive worldwide license agreement with Genentech, a member of the Roche ... but what is driving such a strong gain in the stock is that this could be …
She declined to comment on the settlement figure. Genentech shares rose $4.375 to $76.125 on the New York Stock Exchange yesterday. UC's Board of Regents is expected to consider the offer at meetings tomorrow and Friday. The …